Related Experiment Videos

[Correlation of inactivation of CDKN2/p16 gene by methylation and lung cancers]

C Su1, X Shan

  • 1Department of Molecular Biology, Nanjing 81 Hospital, Nanjing, Jiangsu, 210002 P.R. China. sucq@jlonline.com

Abstract

Insights

Methylation of the CDKN2/p16 gene was observed in 23.6% of lung cancer cases. This gene alteration may play a role in lung cancer development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Context:

  • Lung cancer is a leading cause of cancer-related mortality worldwide.
  • The CDKN2/p16 gene is a tumor suppressor involved in cell cycle regulation.
  • Gene methylation is a key epigenetic mechanism influencing gene expression.

Purpose:

  • To investigate the association between the methylation status of the CDKN2/p16 gene and the occurrence of lung cancer.
  • To determine the frequency of CDKN2/p16 gene methylation in lung cancer patients.

Summary:

  • Genomic DNA from 89 lung cancer patients was analyzed for CDKN2/p16 gene methylation using methylation-sensitive enzymes and Southern blotting.
  • Methylation of the CDKN2/p16 gene was detected in 21 out of 89 cases (23.6%).
  • Notably, 40.5% of P16-negative lung cancer cases exhibited CDKN2/p16 gene methylation.

Impact:

  • The findings suggest that CDKN2/p16 gene methylation is a significant epigenetic event in lung carcinogenesis.
  • Methylation of the CDKN2/p16 gene's 5' CpG island may represent an important mechanism for gene inactivation.
  • This epigenetic alteration could contribute to the initiation and progression of lung cancer.

Related Concept Videos